PMID- 34183497
OWN - NLM
STAT- MEDLINE
DCOM- 20220308
LR  - 20230902
IS  - 1473-5741 (Electronic)
IS  - 0959-4973 (Print)
IS  - 0959-4973 (Linking)
VI  - 33
IP  - 1
DP  - 2022 Jan 1
TI  - Comorbidities and mortality risk among extensive-stage small-cell lung cancer 
      patients in mainland China: impacts of hypertension, type 2 diabetes mellitus, 
      and chronic hepatitis B virus infection.
PG  - 80-90
LID - 10.1097/CAD.0000000000001133 [doi]
AB  - The present study investigated the impact of major comorbidities, including 
      hypertension, type 2 diabetes mellitus (T2DM), and chronic hepatitis B virus 
      (HBV) infection, on the progression-free survival (PFS) and overall survival (OS) 
      of extensive-stage small-cell lung cancer (ES-SCLC) patients in China. Patients 
      having a pathologic diagnosis of ES-SCLC between 2009 and 2017 were enrolled and 
      grouped according to their specific comorbidities. The PFS and OS for each group 
      were evaluated using the Kaplan-Meier method and Cox proportional hazard models. 
      In total, 632 patients were analyzed. The median PFS (mPFS) of these patients was 
      9 months [95% confidence interval (CI), 6-12 months]. The mPFS of patients 
      without hypertension or T2DM was 9 months; conversely, it was significantly 
      reduced for patients with hypertension [7 months (P < 0.0001)] or T2DM [5 months 
      (P < 0.0001)]. However, mPFS was not significantly different between patients 
      with and without HBV infection (P = 0.2936). A similar trend was observed for OS 
      as well. Further multivariate analyses showed that the OS of patients with 
      hypertension [hazard ratio (HR), 1.344; 95% CI, 1.073-1.683; P = 0.010] or T2DM 
      (HR, 1.455; 95% CI, 1.134-1.868; P = 0.003) was significantly shorter than that 
      of patients without these comorbidities. Accordingly, mortality risk was the 
      highest in patients with concurrent hypertension and T2DM (HR, 1.665; 95% CI, 
      1.037-2.672; P = 0.00058). Our study found that hypertension and T2DM may be 
      associated with a worse prognosis in ES-SCLC patients. Considerable attention 
      should be paid to the accompanying anti-comorbidity therapies available for 
      patients with ES-SCLC.
CI  - Copyright (c) 2020 The Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Xiu, Weigang
AU  - Xiu W
AD  - Department of Thoracic Oncology and State Key Laboratory of Biotherapy, Cancer 
      Center, West China Hospital, Sichuan University, Chengdu, PR China.
FAU - Huang, Yin
AU  - Huang Y
FAU - Li, Yanying
AU  - Li Y
FAU - Yu, Min
AU  - Yu M
FAU - Gong, Youling
AU  - Gong Y
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Anticancer Drugs
JT  - Anti-cancer drugs
JID - 9100823
SB  - IM
MH  - Adult
MH  - Aged
MH  - China/epidemiology
MH  - Diabetes Mellitus, Type 2/*epidemiology/pathology
MH  - Female
MH  - Hepatitis B, Chronic/*epidemiology
MH  - Humans
MH  - Hypertension/*epidemiology
MH  - Kaplan-Meier Estimate
MH  - Lung Neoplasms/*epidemiology/mortality
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Progression-Free Survival
MH  - Small Cell Lung Carcinoma/*epidemiology/mortality/pathology
PMC - PMC8670332
COIS- There are no conflicts of interest.
EDAT- 2021/06/30 06:00
MHDA- 2022/03/09 06:00
PMCR- 2021/12/14
CRDT- 2021/06/29 05:54
PHST- 2021/06/30 06:00 [pubmed]
PHST- 2022/03/09 06:00 [medline]
PHST- 2021/06/29 05:54 [entrez]
PHST- 2021/12/14 00:00 [pmc-release]
AID - 00001813-202201000-00009 [pii]
AID - 10.1097/CAD.0000000000001133 [doi]
PST - ppublish
SO  - Anticancer Drugs. 2022 Jan 1;33(1):80-90. doi: 10.1097/CAD.0000000000001133.